These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 15153715

  • 21. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P, Stipa E, La Presa M, Bianchi M, Di Giulio C, Stasi R, Amadori S.
    Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
    [Abstract] [Full Text] [Related]

  • 22. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R, Pagano A, Stipa E, Amadori S.
    Blood; 2001 Aug 15; 98(4):952-7. PubMed ID: 11493438
    [Abstract] [Full Text] [Related]

  • 23. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
    Latifzadeh SZ, Entezari V.
    Clin Appl Thromb Hemost; 2006 Oct 15; 12(4):489-92. PubMed ID: 17000895
    [Abstract] [Full Text] [Related]

  • 24. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y, Karapinar TH, Oymak Y, Toret E, Demirag B, Ince D, Ozcan E, Moueminoglou N, Koker SA, Vergin C.
    Blood Coagul Fibrinolysis; 2016 Jun 15; 27(4):431-5. PubMed ID: 26656905
    [Abstract] [Full Text] [Related]

  • 25. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
    Aggarwal A, Catlett JP.
    South Med J; 2002 Oct 15; 95(10):1209-12. PubMed ID: 12425512
    [Abstract] [Full Text] [Related]

  • 26. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
    Kuwana M, Iki S, Urabe A.
    Am J Hematol; 2007 Sep 15; 82(9):846-8. PubMed ID: 17506067
    [Abstract] [Full Text] [Related]

  • 27. Management of adult idiopathic thrombocytopenic purpura.
    Nakhoul IN, Kozuch P, Varma M.
    Clin Adv Hematol Oncol; 2006 Feb 15; 4(2):136-44, 153. PubMed ID: 16728922
    [Abstract] [Full Text] [Related]

  • 28. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct 15; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 29. Does rituximab aggravate pre-existing hypogammaglobulinaemia?
    Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F, Noorani S, Krishna MT, Huissoon A.
    J Clin Pathol; 2010 Mar 15; 63(3):275-7. PubMed ID: 20203231
    [Abstract] [Full Text] [Related]

  • 30. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
    Kawachi Y, Ide M, Uchida T, Setsu K.
    Rinsho Ketsueki; 2003 Jan 15; 44(1):31-3. PubMed ID: 12649836
    [Abstract] [Full Text] [Related]

  • 31. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb 15; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

  • 32. Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab.
    Iesato K, Hatakeyama N, Yamamoto M, Hori T, Inazawa N, Tsutsumi H, Suzuki N.
    Pediatr Blood Cancer; 2009 Aug 15; 53(2):203-5. PubMed ID: 19301247
    [Abstract] [Full Text] [Related]

  • 33. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS.
    Acta Haematol; 2006 Aug 15; 115(1-2):46-52. PubMed ID: 16424649
    [Abstract] [Full Text] [Related]

  • 34. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N, Evangelista ML, Amadori S, Stasi R.
    Curr Opin Hematol; 2007 Nov 15; 14(6):642-6. PubMed ID: 17898569
    [Abstract] [Full Text] [Related]

  • 35. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F.
    Eur J Haematol Suppl; 2008 Feb 15; (69):19-26. PubMed ID: 18211569
    [Abstract] [Full Text] [Related]

  • 36. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
    Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O.
    J Thromb Thrombolysis; 2009 Apr 15; 27(3):329-33. PubMed ID: 18311541
    [Abstract] [Full Text] [Related]

  • 37. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
    Moschovi M, Trimis G, Pergantou H, Platokouki H, Vrachnou E, Tzortzatou-Stathopoulou F.
    J Paediatr Child Health; 2005 Jul 15; 41(7):384-6. PubMed ID: 16014149
    [Abstract] [Full Text] [Related]

  • 38. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
    Pusiol A, Cesaro S, Nocerino A, Picco G, Zanesco L, Bisogno G.
    Eur J Pediatr; 2004 Jun 15; 163(6):305-7. PubMed ID: 15346911
    [Abstract] [Full Text] [Related]

  • 39. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun 15; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 40. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
    Clausen MR, Segel E, Brandsborg M, d'Amore F.
    Eur J Haematol; 2011 Mar 15; 86(3):256-9. PubMed ID: 21166717
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.